SBIR/STTR Research Award
SanFlow: A Therapeutic Agent for Use in the Field for Traumatic Brain Injury
Award amount
$999,817Program and phase
SBIR · Phase IIAward year
2019Award details
- Awarding agency
- Department of Defense
- Branch
- Defense Health Agency
- Recipient company
- ANTIRADICAL THERAPEUTICS LLC
- Proposal award date
- 2018-12-03
- Contract end date
- 2021-05-02
- UEI
- X9QNA95VGLP8
- Solicitation number
- 17.1
- Topic code
- DHA17-011
Research abstract
An ideal therapeutic for traumatic brain injury (TBI) accompanied by hemorrhagic shock (HS) should serve both as a resuscitation fluid to restore perfusion pressure while directly protecting the brain from secondary injury. Previous work in mice demonstra
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Point of Injury Therapy to Maintain and Stabilize Moderate-Severe Traumatic Brain Injury (TBI) Casualties.
- Point of Injury Therapy to Maintain and Stabilize Moderate-Severe Traumatic Brain Injury (TBI) Casualties.
- Cerebral Trauma Recovery (CereTRec) drug delivery system
Research funding history
2 SBIR/STTR records share this UEI (2017–2019). Reported award amounts total $1,149,817. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Defense